The development of newer antifungal drugs is creating new potential combination therapies
to combat the dismal mortality rate associated with invasive aspergillosis (IA). The efficacy of …

Background: Treatment of invasive aspergillosis is frequently unsuccessful, so innovations
in therapy are needed. Clinical studies demonstrate that itraconazole may be an effective …

Antifungal Combination Therapy for Invasive Aspergillosis | Clinical Infectious Diseases |
Oxford Academic Skip to Main Content Advertisement Oxford Academic Journals Books …

BACKGROUND: Because treatment outcomes of invasive aspergillosis (IA) remain
suboptimal, clinicians have resorted to the use of combination antifungal therapy. We …

Background. Aspergillosis therapy with amphotericin, azoles, or echinocandins is
associated with substantial mortality, ranging from 30% to 80%, depending on the stage of …

Invasive aspergillosis (IA) is an acute infection affecting patients who are
immunocompromised, as a result of receiving chemotherapy for malignancy, or …

Background. In a previous randomized trial of voriconazole versus amphotericin B
deoxycholate for primary therapy of invasive aspergillosis, voriconazole demonstrated …

This article has been corrected. The original version (PDF) is appended to this article as a
Supplement. Background: Invasive aspergillosis (IA) is associated with poor outcomes in …

Invasive aspergillosis is generally a life-threatening invasive opportunistic mycosis affecting
principally the upper and lower respiratory tract. Therapeutic response rates vary …

Abstract background: Invasive aspergillosis is the most common invasive mould infection
and a major cause of mortality in immunocompromised patients. Response to amphotericin …